Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Jesús F. San Miguel et al.|New England Journal of Medicine|2022Cited by 1.2k
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple MyelomaPhilippe Moreau, Amrita Krishnan, Saad Z. Usmani et al.|Blood|2021Cited by 40